1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756–70.
2. D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763–86.
3. Marchal Bressenot A. Which evidence for a treat to target strategy in ulcerative colitis?. Best Pract Res Clin Gastroenterol. 2018;32–33:3–8.
4. Darr U, Khan N. Treat to target in inflammatory bowel disease: an updated review of literature. Curr Treat Options Gastroenterol. 2017;15(1):116–25.
5. Reinisch W, Gottlieb K, Colombel JF, Danese S, Panaccione R, Panes J, et al. Comparison of the EMA and FDA guidelines on ulcerative colitis drug development. Clin Gastroenterol Hepatol. 2019;17(9):1673–79.e1.